Business Description
CERo Therapeutics Holdings Inc
NAICS : 541713
SIC : 2833
Description
CERo Therapeutics Holdings Inc is an innovative immunotherapy company advancing the development of next-generation engineered T-cell therapeutics for the treatment of cancer. Its proprietary approach to T cell engineering, which enables it to integrate certain desirable characteristics of both innate and adaptive immunity into a single therapeutic construct, is designed to engage the body's full immune repertoire to achieve optimized cancer therapy.
Financial Strength
5/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | 2.26 | |||||
| Equity-to-Asset | -3.07 | |||||
| Debt-to-Equity | -0.09 | |||||
| Debt-to-EBITDA | -0.28 | |||||
| Interest Coverage | N/A |
N/A
|
N/A
| |||
| Piotroski F-Score | N/A/9 | |||||
| WACC vs ROIC | ||||||
Growth Rank
| Name | Current | Vs Industry | Vs History |
|---|
Momentum Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 5-Day RSI | 27.83 | |||||
| 9-Day RSI | 32.59 | |||||
| 14-Day RSI | 34.48 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 6.08 | |||||
| Quick Ratio | 6.08 | |||||
| Cash Ratio | 5.86 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History |
|---|
Profitability Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| ROA % | -66.6 | |||||
| ROIC % | -218.33 | |||||
| ROC (Joel Greenblatt) % | -268.26 | |||||
| ROCE % | -73.62 |
GF Value Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| EV-to-EBIT | -1.52 | |||||
| EV-to-EBITDA | -1.67 | |||||
| EV-to-FCF | -1.47 | |||||
| Earnings Yield (Greenblatt) % | -65.79 | |||||
| FCF Yield % | -61.49 |
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsGurus Latest Trades with NAS:CERO
You need a Premium membership or above to view this section.
Take a 7-Day Free Trial
No Available Data
Peter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
CERo Therapeutics Holdings Inc Executives
DetailsGF Value
Analyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil $) | |||
| EPS (TTM) ($) | -1.149 | ||
| Beta | 0 | ||
| Volatility % | 0 | ||
| 14-Day RSI | 34.48 | ||
| 14-Day ATR ($) | 0.310316 | ||
| 20-Day SMA ($) | 1.776795 | ||
| 12-1 Month Momentum % | 0 | ||
| 52-Week Range ($) | 1.33 - 12.38 | ||
| Shares Outstanding (Mil) | 14.72 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 9999 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
CERo Therapeutics Holdings Inc Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
CERo Therapeutics Holdings Inc Stock Events
| Event | Date | Price($) | ||
|---|---|---|---|---|
| No Event Data | ||||
CERo Therapeutics Holdings Inc Frequently Asked Questions
What is CERo Therapeutics Holdings Inc(CERO)'s stock price today?
The current price of CERO is $1.37. The 52 week high of CERO is $12.38 and 52 week low is $1.33.
When is next earnings date of CERo Therapeutics Holdings Inc(CERO)?
The next earnings date of CERo Therapeutics Holdings Inc(CERO) is .
Does CERo Therapeutics Holdings Inc(CERO) pay dividends? If so, how much?
CERo Therapeutics Holdings Inc(CERO) does not pay dividend.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers